Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat with Chemotherapy in Pediatric Relapsed/Refractory AML/MDS
NCT03813147Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pevonedistat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities at 35 days, Adverse Events Attributable to MLN4924 at 70 days and 5 more. Started May 2019; status: completed.
02
Drugs
pevonedistat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03813147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813147.